PERI-OPERATIVE CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER: OVERVIEW AND A RATIONALE FOR THE NEED TO SEEK ALTERNATIVE TREATMENT: MAGNOLIA CLINICAL TRIAL

I. A. Korneyev; Корнеев И. А.; I. A. Aboyan; Абоян И. А.; B. Ya. Alekseev; Алексеев Б. Я.; O. I. Apolikhin; Аполихин О. И.; B. K. Komyakov; Комяков Б. К.; V. B. Matveev; Матвеев В. Б.; M. Colombel; Colombel M.; A. Heidenreich; Heidenreich A.; L. Martínez-Piñeiro; Martínez-Piñeiro L.; M. Babjuk; Babjuk M.; C. Surcel; Surcel C.; P. Yakovlev; Yakovlev P.; R. Colombo; Colombo R.; P. Radziszewski; Radziszewski P.; F. Witjes; Witjes F.; P. Mulders; Mulders P.; R. Schipper; Schipper R.; W. Witjes; Witjes W.

doi:10.17650/1726-9776-2013-9-4-71-74

PERI-OPERATIVE CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER: OVERVIEW AND A RATIONALE FOR THE NEED TO SEEK ALTERNATIVE TREATMENT: MAGNOLIA CLINICAL TRIAL

Authors: Korneyev I.A.¹, Aboyan I.A.², Alekseev B.Y.³, Apolikhin O.I.⁴, Komyakov B.K.⁵, Matveev V.B.⁶, Colombel M.⁷, Heidenreich A.⁸, Martínez-Piñeiro L.⁹, Babjuk M.¹⁰, Surcel C.¹¹, Yakovlev P.¹², Colombo R.¹³, Radziszewski P.¹⁴, Witjes F.¹⁵, Mulders P.¹⁶, Schipper R.¹⁶, Witjes W.¹⁶
Affiliations:
1. Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation
2. Zdorovye (Health) Clinical Diagnostic Center, Nizhny Novgorod
3. P.A. Herzen Moscow Oncology Research Institute, Moscow
4. Research Institute of Urology, Ministry of Health of the Russian Federation, Moscow
5. I.I. Mechnikov North-Western State Medical University, Ministry of Health of the Russian Federation, Saint Petersburg
6. N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
7. Hôpital Edouard Herriot, Lyon
8. Universitätsklinikum der RWTH Aachen, Aachen
9. Hospital Infanta Sofia, Madrid
10. Urologická klinika FN Motol, Prague
11. Fundeni Clinical Institute, Bucharest
12. Kiev Municipal Oncology Hospital, Kiev
13. University Vita Salute San Raffaele Hospital, Milan
14. Medical University Warsaw, Warsaw
15. UMC St. Radboud, Nijmegen
16. EAU Research Foundation, Arnhem
Issue: Vol 9, No 4 (2013)
Pages: 71-74
Section: REVIEW
Published: 30.12.2013
URL: https://oncourology.abvpress.ru/oncur/article/view/152
DOI: https://doi.org/10.17650/1726-9776-2013-9-4-71-74
ID: 152

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The paper gives an overview of peri-operative chemotherapy in patients with muscle-invasive bladder cancer (MIBC) as insufficient option, demonstrates a clinical need for the development of more efficacious and safe treatment and introduces a MAGNOLIA study proposed by the European Association of Urology Research Fund in a concept of MIBC immunotherapy. The MAGNOLIA trial conducted in 56 research centers of 10 countries assesses whether adjuvant immunotherapy with recMAGE-A3+AS15 vaccine is safe and effective and improves outcome of patients with MAGE-A3 positive MIBC after cystectomy. 60 of 273 patients have been enrolled. The trial has to be continued to elaborate a general peri-operative treatment strategy for MIBC.

Keywords

invasive bladder cancer, cystectomy, peri-operative chemotherapy, MAGNOLIA clinical trial, immunotherapy

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

PERI-OPERATIVE CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER: OVERVIEW AND A RATIONALE FOR THE NEED TO SEEK ALTERNATIVE TREATMENT: MAGNOLIA CLINICAL TRIAL

Full Text

Abstract

Keywords

About the authors

References

Supplementary files